Literature DB >> 32891591

Mucormycosis: An 8-year experience of a tertiary care centre in Saudi Arabia.

Fatehi Elzein1, Ahmed Albarrag2, Kiran Kalam3, Maria Arafah2, Abeer Al-Baadani3, Nazik Eltayeb3, Fadel Aloteibi4, Abdulrahman Alrashed3, Rashid Al Abdullah3, Shuaa Alasiri4.   

Abstract

Mucormycosis is a rare fungal infection with an extremely high morbidity and mortality. Data on the burden of the disease in the Arab world is lacking. The aim of this study is to highlight the incidence and outcome of this infection in a tertiary care center in the Kingdom of Saudi Arabia (KSA). In this retrospective study we included all mucormycosis cases admitted to our center between January 2013 and December 2019. A total of 18 proven patients with a median age of 43.5 years (range 13-72 years, 72% males) were identified. The most common presentation was cutaneous and rhino-orbito-cerebral, followed by gastrointestinal mucormycosis. Apophysomyces variabilisRhizopus oryzae) were the main fungal isolates on molecular testing. Trauma was the chief underlying etiology (41.0%) with motor vehicle accident (MVCs) being the predominant type (43.0%). For this reason, most of our patients were young with cutaneous disease and had a better prognosis. All patients received liposomal amphotericin B alone or in combination with other antifungal agents. Repeated aggressive debridement and reversal of the underlying factor was attempted in all patients. This underscores the lower mortality (27.8%) seen in this group. The diagnosis of Mucorales infection is challenging. A high index of suspicion with prompt treatment is required to improve the high mortality of this aggressive disease. Further studies are needed to understand the epidemiology and outcome of this disease in Saudi Arabia.
Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Epidemiology; Mucormycosis; Saudi Arabia; Trauma

Mesh:

Substances:

Year:  2020        PMID: 32891591     DOI: 10.1016/j.jiph.2020.08.002

Source DB:  PubMed          Journal:  J Infect Public Health        ISSN: 1876-0341            Impact factor:   3.718


  6 in total

1.  Surgical & medical management of ROCM (Rhino-orbito-cerebral mucormycosis) epidemic in COVID-19 era and its outcomes - a tertiary care center experience.

Authors:  Kapil Soni; Aparna Das; Vidhu Sharma; Amit Goyal; Bikram Choudhury; Ankita Chugh; Deepak Kumar; Taruna Yadav; Vidhi Jain; Ashwini Agarwal; Mayank Garg; Kavita Bhatnagar; Poonam Elhence; Pradeep Kumar Bhatia; Mahendra Kumar Garg; Sanjeev Misra
Journal:  J Mycol Med       Date:  2021-12-25       Impact factor: 3.746

2.  The diversity and outcome of post-covid mucormycosis: A case report.

Authors:  Reem Hassan Saad; Fahmy A Mobarak
Journal:  Int J Surg Case Rep       Date:  2021-10-18

3.  Mucormycosis in pediatric oncology patients: a hospital outbreak investigation report.

Authors:  Ahmed I H Saleem; Asim Alsaedi; Maher Alharbi; Shaker Abdullah; Ali Al Rabou; Mona AlDabbagh
Journal:  Infect Prev Pract       Date:  2021-11-20

4.  Mucormycosis in COVID-19 pandemic: study at tertiary hospital in India.

Authors:  Reshma P Chavan; Shivraj M Ingole; Hamna Abdul Nazir; Wilson V Desai; Gajanan S Kanchewad
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-02-05       Impact factor: 3.236

5.  Clinical characteristics and outcome of mucormycosis: A multi-center retrospective analysis in Saudi Arabia over 11 years.

Authors:  Reem Abanamy; Abdulrahman Alsaud; Rawan Alabdulali; Mohammed Alsobaie; Bassam Alalwan; Sameera Aljohani; Saeed Alshieban; Hanan Turkistani; Abdullah Almohaizeie; Mohammad Bosaeed; Fahad AlRabiah
Journal:  IJID Reg       Date:  2022-07-08

Review 6.  New insights on mucormycosis and its association with the COVID-19 pandemic.

Authors:  Mona G Alshahawey; Ghadir S El-Housseiny; Noha S Elsayed; Mohammad Y Alshahrani; Lamia Mel Wakeel; Khaled M Aboshanab
Journal:  Future Sci OA       Date:  2021-12-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.